Shares of Charles River CRL were unchanged after the company reported Q2 results.
Earnings per share increased 65.19% year over year to $2.61, which beat the estimate of $2.38.
Revenue of $914,607,000 rose by 33.99% from the same period last year, which beat the estimate of $880,650,000.
The upcoming fiscal year's EPS expected to be between $10.10 and $10.35.
The upcoming fiscal year's revenue expected to be between $3,523,000,000 and $3,582,000,000.
How To Listen To The Conference Call
Date: Aug 04, 2021
Time: 09:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/56n4zx8c
52-week high: $412.05
Company's 52-week low was at $197.33
Price action over last quarter: Up 19.13%
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.